Capitalcube gives AngioDynamics, Inc. a score of 19.
Our analysis is based on comparing AngioDynamics, Inc. with the following peers – Vascular Solutions, Inc., LeMaitre Vascular, Inc., Merit Medical Systems, Inc., C. R. Bard, Inc., Teleflex Incorporated, ICU Medical, Inc., Boston Scientific Corporation and Johnson & Johnson (VASC-US, LMAT-US, MMSI-US, BCR-US, TFX-US, ICUI-US, BSX-US and JNJ-US).
AngioDynamics, Inc. has a fundamental score of 19 and has a relative valuation of UNDERVALUED.
Access our research and ratings on AngioDynamics, Inc.
- Compared to peers, relative outperformance over the last year has faded more recently.
- AngioDynamics, Inc. trades at a lower Price/Book multiple (1.24) than its peer median (4.15).
- ANGO-US‘s EBITDA-based price multiple implies around peer median growth. The market does not seem to expect much improvement in the company’s below peer median EBITDA-based returns.
- ANGO-US has relatively low profit margins and median asset efficiency.
- Compared with its chosen peers, the company’s annual revenues and earnings change at a slower rate, implying a lack of strategic focus and/or lack of execution success.
- ANGO-US‘s return on assets currently and over the past five years has trailed the peer median and suggests the company might be operationally challenged relative to its peers.
- The company’s relatively low gross and pre-tax margins suggest a non-differentiated product portfolio and not much control on operating costs relative to peers.
- While ANGO-US‘s revenues growth has been below the peer median in the last few years, the market still gives the stock a Price/EBITDA ratio that is around peer median and seems to see the company as a long-term strategic bet.
- The company’s relatively low level of capital investment and below peer median returns on capital suggest that the company is in maintenance mode.
- ANGO-US has the financial and operating capacity to borrow quickly.
Access our research and ratings on AngioDynamics, Inc.
Leverage & Liquidity
ANGO-US has the financial and operating capacity to borrow quickly.
- With debt at a relatively low 17.20% of its enterprise value compared to an overall benchmark of 25% (Note: The peer median is currently 9.66%), and a well-cushioned interest coverage level of 4.29x, ANGO-US can probably borrow quickly. We classify the company as Quick & Able in terms of its capacity to raise additional debt.
- Of the 8 chosen peers for the company, only 5 of the stocks have an outstanding debt balance. Companies with no debt include VASC-US, LMAT-US and ICUI-US.
ANGO-US has moved to a Quick & Able from a relatively high liquidity profile at the recent year-end.
- ANGO-US‘s interest coverage is less than (but within one standard deviation of) its five-year average interest coverage of 9.49x.
- Though its interest coverage has remained relatively stable at 4.29x compared to 2016, its peer median has decreased to 17.97x from 20.77x during this period.
- Interest coverage rose 2.80 points relative to peers.
- ANGO-US‘s debt-EV is its lowest relative to the last five years and compares to a high of 28.50% in 2013.
- Though its debt-EV decreased to 17.20% from 23.21% (in 2016), its peer median remained relatively stable during this period at 9.66%.
- Relative to peers, debt-EV fell 5.91 percentage points.
Access the detailed analysis for AngioDynamics, Inc.
Key Liquidity Items
|Company||Debt/Enterprise Value (%)||Current Ratio||Interest Coverage (x)||Cash Flow To Total Debt (%)|
|Vascular Solutions, Inc.||0||6.37||No interest exp||999|
|LeMaitre Vascular, Inc.||0||5.66||No interest exp||999|
|Merit Medical Systems, Inc.||23.52||2.71||4.04||23.69|
|C. R. Bard, Inc.||9.66||2.63||17.97||60.23|
|ICU Medical, Inc.||0||15.47||No interest exp||999|
|Boston Scientific Corporation||14.43||1.05||4.9||6.44|
|Johnson & Johnson||8.76||2.73||27.65||72.41|
|Best In Class||8.76||15.47||No interest exp||999|
Looking for more metrics and analysis for AngioDynamics, Inc.?
AngioDynamics, Inc. engages in the business of medical devices. Its activities include design, manufactures, and sale of medical, surgical and diagnostic devices. The company focuses on devices in the field of vascular access, peripheral vascular, oncology, and surgery. AngioDynamics was founded by Eamonn P. Hobbs in 1988 and is headquartered in Latham, NY.
The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party’s use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any our reports, you’re agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website www.analytixinsight.com.